TmPSMA-02 in mCRPC

Summary

This is a Phase I, open-label dose finding study to assess the safety, tolerability, manufacturing feasibility, and preliminary efficacy of TmPSMA-02 CAR T cells in patients with metastatic castrate-resistant prostate cancer (mCRPC). Up to 4 total dose levels will be evaluated using a 3+3 dose escalation design.

Timeline

Start

2024-01-31

Primary completion

2027-01-31

Completion

2042-01-31

Publications

• Wang Y, Zhao G, Wang S, Li N. DNTGF-betaR armored CAR-T cell therapy against tumors from bench to bedside. J Transl Med. 2024 Jan 11;22(1):45. doi: 10.1186/s12967-023-04829-6. No abstract available.

Drugs

Indications